enGene Therapeutics Inc. Common Stock (ENGN) Stock
NASDAQ · ENGN
1.91
Fundamentals
Market cap
$128.00M
Price / Earnings ratio
-1.0x
Price / Sales ratio
N/A
Price / Book ratio
0.6x
Return on assets
-0.5%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About enGene Therapeutics Inc. Common Stock
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
SectorHealthcare
IndustryBiotechnology
Employees81
CEOMr. Ronald H. W. Cooper
IPO DateNov 1, 2023
HeadquartersMontreal, QC
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Ronald H. W. Cooper | President, CEO & Director | 1963 |
| Dr. William J. Grossman M.D., Ph.D. | Interim Chief Medical Officer & Director | 1970 |
| Dr. Anthony T. Cheung Ph.D. | Co-Founder & Chief Scientific Officer | 1972 |
| Ms. Kathleen Richton | Senior VP of Finance, Principal Accounting & Financial Officer and Controller | 1978 |
| Ms. Joan Connolly | Chief Technology Officer | 1970 |
| Ms. Tara Place M.B.A. | Senior VP of Human Resources | — |
| Mr. Matthew Boyd | Chief Regulatory Officer | 1974 |
| Ms. Jill Buck | Chief Development Officer | 1974 |
| Ms. Amy Pott | Chief Global Commercialization Officer | 1976 |
Fundamentals
Valuation
Market cap$128.00M
Price-to-sales ratioN/A
Price-to-book value0.56
Price-earnings ratio-1.00
Return on Equity-56.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-2.07
Income Statement
Average volume695,885
EBITDA$-122.69M
1 year high (52w)$12.25
1 year low (52w)$1.40
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



